Literature DB >> 8262693

The effect of ebselen on polymorphonuclear leukocyte migration to joints in rats with adjuvant arthritis.

J X Gao1, A C Issekutz.   

Abstract

We have previously reported that ebselen (PZ 51,2-Phenyl-1,2- Benzoisoselenazol-3-(2H)-one), a selinyl organic compound with anti-inflammatory properties, inhibited human polymorphonuclear leukocyte (PMNL) adhesion to and migration through cytokine-activated human umbilical vein endothelium in vitro. Here we investigated the in vivo effect of ebselen on PMNL migration into arthritic joints and dermal inflammation in rats with adjuvant arthritis. The rats were immunized with adjuvant (Mycobacteriaum butyricum in mineral oil) and 13 days later, when arthritis was fully developed, treatment (p.o.) with ebselen, indomethacin or vehicle was initiated. The migration of 51Cr-labelled blood PMNL purified from arthritic donors and extravasation of 125I-labelled HSA in arthritic joints and dermal inflammatory reactions was quantitatively measured. Treatment of rats with 100 mg/kg/day ebselen for 3 days, inhibited by 72-79% the PMNL migration into arthritic joints and tail (spondylitis) and by 50-60% into dermal inflammatory reactions induced with zymosan-activated rat serum (ZAS; C5adesArg), endotoxin (LPS) or IL-1 alpha. The inhibitory effect of ebselen was dose-dependent, because treatment of rats with 100 mg/kg/day ebselen caused significantly more inhibition of PMNL migration than did 30 mg/kg/day, although this dose was still effective. Ebselen inhibited PMNL migration into arthritic joints and dermal inflammation within 3 h of initial oral administration (100 mg/kg). However, ebselen did not suppress plasma albumin extravasation into arthritic joints and dermal inflammatory reactions. Compared to ebselen, treatment with indomethacin (2 mg/kg/day) was significantly less effective in inhibiting PMNL accumulation in joints, but in contrast to ebselen, indomethacin did inhibit plasma albumin extravasation into carpal and talar joints. The results suggest that ebselen effectively and rapidly inhibits PMNL migration in vivo, as also observed in vitro, and that it has anti-inflammatory actions distinct from classic nonsteroidal anti-inflammatory drugs such as indomethacin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262693     DOI: 10.1016/0192-0561(93)90016-r

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

Review 2.  Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease.

Authors:  Itsuro Kazama
Journal:  J Physiol Sci       Date:  2014-08-06       Impact factor: 2.781

3.  Complete remission of human parvovirus b19 associated symptoms by loxoprofen in patients with atopic predispositions.

Authors:  Itsuro Kazama; Naoko Sasagawa; Toshiyuki Nakajima
Journal:  Case Rep Med       Date:  2012-04-24

4.  Nonsteroidal Anti-Inflammatory Drugs Quickly Resolve Symptoms Associated with EBV-Induced Infectious Mononucleosis in Patients with Atopic Predispositions.

Authors:  Itsuro Kazama; Chieko Miura; Toshiyuki Nakajima
Journal:  Am J Case Rep       Date:  2016-02-14

5.  Evaluation of Artemisia amygdalina D. for Anti-Inflammatory and Immunomodulatory Potential.

Authors:  Khan Mubashir; Bashir A Ganai; Khalid Ghazanfar; Seema Akbar; Akhtar H Malik; Akbar Masood
Journal:  ISRN Inflamm       Date:  2013-10-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.